Cargando…
Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progress...
Autores principales: | Mongre, Raj Kumar, Mishra, Chandra Bhushan, Shukla, Arvind Kumar, Prakash, Amresh, Jung, Samil, Ashraf-Uz-Zaman, Md, Lee, Myeong-Sok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584061/ https://www.ncbi.nlm.nih.gov/pubmed/34769090 http://dx.doi.org/10.3390/ijms222111659 |
Ejemplares similares
-
Novel Carbazole-Piperazine Hybrid Small Molecule Induces Apoptosis by Targeting BCL-2 and Inhibits Tumor Progression in Lung Adenocarcinoma In Vitro and Xenograft Mice Model
por: Mongre, Raj Kumar, et al.
Publicado: (2019) -
Identifying the Novel Inhibitors Against the Mycolic Acid Biosynthesis Pathway Target “mtFabH” of Mycobacterium tuberculosis
por: Kumar, Niranjan, et al.
Publicado: (2022) -
Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in vitro and in vivo studies
por: Mishra, Chandra Bhushan, et al.
Publicado: (2021) -
Rheumatologie – quo vadis? Gesundheitssystem – quo vadis?
por: Puchner, Rudolf
Publicado: (2023) -
Quo vadis?
por: Sienkiewicz, Henryk, 1846-1916
Publicado: (1943)